Barry S T, Ludbrook S B, Murrison E, Horgan C M
Molecular Pharmacology, GlaxoWellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom.
Exp Cell Res. 2000 Aug 1;258(2):342-51. doi: 10.1006/excr.2000.4941.
The integrin alpha4beta1 is involved in mediating exfiltration of leukocytes from the vasculature. It interacts with a number of proteins up-regulated during the inflammatory response including VCAM-1 and the CS-1 alternatively spliced region of fibronectin. In addition it binds the multifunctional protein osteopontin (OPN), which can act as both a cytokine and an extracellular matrix molecule. Here we map the region of human OPN that supports cell adhesion via alpha4beta1 using GST fusion proteins. We show that alpha4beta1 expressed in J6 cells interacts with intact OPN when the integrin is in a high activation state, and by deletion mapping that the alpha4beta1 binding region in OPN lies between amino acid residues 125 and 168 (aa125-168). This region contains the central RGD motif of OPN, which also interacts with integrins alphavbeta3, alphavbeta5, alphavbeta1, alpha8beta1, and alpha5beta1. Mutating the RGD motif to RAD had no effect on the interaction with alpha4beta1. To define the binding site the region incorporating aa125-168 was divided into 5 overlapping peptides expressed as GST fusion proteins. Two peptides supported adhesion via alpha4beta1, aa132-146, and aa153-168; of these only a synthetic peptide, SVVYGLR (aa162-168), derived from aa153-168 was able to inhibit alpha4beta1 binding to CS-1. These data identify the motif SVVYGLR as a novel peptide inhibitor of alpha4beta1, and the primary alpha4beta1 binding site within OPN.
整合素α4β1参与介导白细胞从脉管系统渗出。它与炎症反应期间上调的多种蛋白质相互作用,包括血管细胞黏附分子-1(VCAM-1)和纤连蛋白的CS-1可变剪接区域。此外,它还结合多功能蛋白骨桥蛋白(OPN),该蛋白既可以作为细胞因子,也可以作为细胞外基质分子。在这里,我们使用谷胱甘肽S-转移酶(GST)融合蛋白绘制了人OPN中通过α4β1支持细胞黏附的区域。我们发现,当整合素处于高激活状态时,J6细胞中表达的α4β1与完整的OPN相互作用,并且通过缺失定位表明,OPN中的α4β1结合区域位于氨基酸残基125和168(aa125-168)之间。该区域包含OPN的中央RGD基序,其也与整合素αvβ3、αvβ5、αvβ1、α8β1和α5β1相互作用。将RGD基序突变为RAD对与α4β1的相互作用没有影响。为了确定结合位点,将包含aa125-168的区域分为5个重叠肽,表达为GST融合蛋白。两个肽通过α4β1支持黏附,即aa132-146和aa153-168;其中只有一个源自aa153-168的合成肽SVVYGLR(aa162-168)能够抑制α4β1与CS-1的结合。这些数据确定基序SVVYGLR是α4β1的新型肽抑制剂,也是OPN内的主要α4β1结合位点。